<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 19:59:33 -0700</creation_date>
  <update_date>2013-01-15 19:59:33 -0700</update_date>
  <accession>HMDBP07491</accession>
  <secondary_accessions>
    <accession>13199</accession>
  </secondary_accessions>
  <protein_type>Unknown</protein_type>
  <synonyms>
    <synonym>BI</synonym>
    <synonym>Brain calcium channel I</synonym>
    <synonym>Calcium channel, L type, alpha-1 polypeptide isoform 4</synonym>
    <synonym>Voltage-gated calcium channel subunit alpha Cav2.1</synonym>
  </synonyms>
  <gene_name>CACNA1A</gene_name>
  <general_function>Involved in ion channel activity</general_function>
  <specific_function>Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1A gives rise to P and/or Q-type calcium currents. P/Q-type calcium channels belong to the 'high-voltage activated' (HVA) group and are blocked by the funnel toxin (Ftx) and by the omega-agatoxin- IVA (omega-Aga-IVA). They are however insensitive to dihydropyridines (DHP), and omega-conotoxin-GVIA (omega-CTx-GVIA)</specific_function>
  <pathways>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB00464</accession>
      <name>Calcium</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04999</accession>
      <name>Loperamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14375</accession>
      <name>Pregabalin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13961</accession>
      <name>O-Desmethylverapamil (D-702)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15374</accession>
      <name>Bepridil</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>cation channel activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>calcium channel activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>voltage-gated calcium channel activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transmembrane transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>substrate-specific transmembrane transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>ion transmembrane transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>ion channel activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cation transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>di-, tri-valent inorganic cation transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>divalent metal ion transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>calcium ion transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>transmembrane transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>establishment of localization</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>ion transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>macromolecular complex</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>protein complex</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>ion channel complex</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>cation channel complex</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>calcium channel complex</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>voltage-gated calcium channel complex</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>intrinsic to membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>integral to membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>cell part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane</description>
      <go_id/>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Membrane</subcellular_location>
    <subcellular_location>Multi-pass membrane protein</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>Chromosome:1</chromosome_location>
    <locus>19p13</locus>
    <gene_sequence>&gt;7518 bp
ATGGCCCGCTTCGGAGACGAGATGCCGGCCCGCTACGGGGGAGGAGGCTCCGGGGCAGCC
GCCGGGGTGGTCGTGGGCAGCGGAGGCGGGCGAGGAGCCGGGGGCAGCCGGCAGGGCGGG
CAGCCCGGGGCGCAAAGGATGTACAAGCAGTCAATGGCGCAGAGAGCGCGGACCATGGCA
CTCTACAACCCCATCCCCGTCCGACAGAACTGCCTCACGGTTAACCGGTCTCTCTTCCTC
TTCAGCGAAGACAACGTGGTGAGAAAATACGCCAAAAAGATCACCGAATGGCCTCCCTTT
GAATATATGATTTTAGCCACCATCATAGCGAATTGCATCGTCCTCGCACTGGAGCAGCAT
CTGCCTGATGATGACAAGACCCCGATGTCTGAACGGCTGGATGACACAGAACCATACTTC
ATTGGAATTTTTTGTTTCGAGGCTGGAATTAAAATCATTGCCCTTGGGTTTGCCTTCCAC
AAAGGCTCCTACTTGAGGAATGGCTGGAATGTCATGGACTTTGTGGTGGTGCTAACGGGC
ATCTTGGCGACAGTTGGGACGGAGTTTGACCTACGGACGCTGAGGGCAGTTCGAGTGCTG
CGGCCGCTCAAGCTGGTGTCTGGAATCCCAAGTTTACAAGTCGTCCTGAAGTCGATCATG
AAGGCGATGATCCCTTTGCTGCAGATCGGCCTCCTCCTATTTTTTGCAATCCTTATTTTT
GCAATCATAGGGTTAGAATTTTATATGGGAAAATTTCATACCACCTGCTTTGAAGAGGGG
ACAGATGACATTCAGGGTGAGTCTCCGGCTCCATGTGGGACAGAAGAGCCCGCCCGCACC
TGCCCCAATGGGACCAAATGTCAGCCCTACTGGGAAGGGCCCAACAACGGGATCACTCAG
TTCGACAACATCCTGTTTGCAGTGCTGACTGTTTTCCAGTGCATAACCATGGAAGGGTGG
ACTGATCTCCTCTACAATAGCAACGATGCCTCAGGGAACACTTGGAACTGGTTGTACTTC
ATCCCCCTCATCATCATCGGCTCCTTTTTTATGCTGAACCTTGTGCTGGGTGTGCTGTCA
GGGGAGTTTGCCAAAGAAAGGGAACGGGTGGAGAACCGGCGGGCTTTTCTGAAGCTGAGG
CGGCAACAACAGATTGAACGTGAGCTCAATGGGTACATGGAATGGATCTCAAAAGCAGAA
GAGGTGATCCTCGCCGAGGATGAAACTGACGGGGAGCAGAGGCATCCCTTTGATGGAGCT
CTGCGGAGAACCACCATAAAGAAAAGCAAGACAGATTTGCTCAACCCCGAAGAGGCTGAG
GATCAGCTGGCTGATATAGCCTCTGTGGGTTCTCCCTTCGCCCGAGCCAGCATTAAAAGT
GCCAAGCTGGAGAACTCGACCTTTTTTCACAAAAAGGAGAGGAGGATGCGTTTCTACATC
CGCCGCATGGTCAAAACTCAGGCCTTCTACTGGACTGTACTCAGTTTGGTAGCTCTCAAC
ACGCTGTGTGTTGCTATTGTTCACTACAACCAGCCCGAGTGGCTCTCCGACTTCCTTTAC
TATGCAGAATTCATTTTCTTAGGACTCTTTATGTCCGAAATGTTTATAAAAATGTACGGG
CTTGGGACGCGGCCTTACTTCCACTCTTCCTTCAACTGCTTTGACTGTGGGGTTATCATT
GGGAGCATCTTCGAGGTCATCTGGGCTGTCATAAAACCTGGCACATCCTTTGGAATCAGC
GTGTTACGAGCCCTCAGGTTATTGCGTATTTTCAAAGTCACAAAGTACTGGGCATCTCTC
AGAAACCTGGTCGTCTCTCTCCTCAACTCCATGAAGTCCATCATCAGCCTGTTGTTTCTC
CTTTTCCTGTTCATTGTCGTCTTCGCCCTTTTGGGAATGCAACTCTTCGGCGGCCAGTTT
AATTTCGATGAAGGGACTCCTCCCACCAACTTCGATACTTTTCCAGCAGCAATAATGACG
GTGTTTCAGATCCTGACGGGCGAAGACTGGAACGAGGTCATGTACGACGGGATCAAGTCT
CAGGGGGGCGTGCAGGGCGGCATGGTGTTCTCCATCTATTTCATTGTACTGACGCTCTTT
GGGAACTACACCCTCCTGAATGTGTTCTTGGCCATCGCTGTGGACAATCTGGCCAACGCC
CAGGAGCTCACCAAGGACGAGCAAGAGGAAGAAGAAGCAGCGAACCAGAAACTTGCCCTA
CAGAAAGCCAAGGAGGTGGCAGAAGTGAGTCCTCTGTCCGCGGCCAACATGTCTATAGCT
GTGAAAGAGCAACAGAAGAATCAAAAGCCAGCCAAGTCCGTGTGGGAGCAGCGGACCAGT
GAGATGCGAAAGCAGAACTTGCTGGCCAGCCGGGAGGCCCTGTATAACGAAATGGACCCG
GACGAGCGCTGGAAGGCTGCCTACACGCGGCACCTGCGGCCAGACATGAAGACGCACTTG
GACCGGCCGCTGGTGGTGGACCCGCAGGAGAACCGCAACAACAACACCAACAAGAGCCGG
GCGGCCGAGCCCACCGTGGACCAGCGCCTCGGCCAGCAGCGCGCCGAGGACTTCCTCAGG
AAACAGGCCCGCTACCACGATCGGGCCCGGGACCCCAGCGGCTCGGCGGGCCTGGACGCA
CGGAGGCCCTGGGCGGGAAGCCAGGAGGCCGAGCTGAGCCGGGAGGGACCCTACGGCCGC
GAGTCGGACCACCACGCCCGGGAGGGCAGCCTGGAGCAACCCGGGTTCTGGGAGGGCGAG
GCCGAGCGAGGCAAGGCCGGGGACCCCCACCGGAGGCACGTGCACCGGCAGGGGGGCAGC
AGGGAGAGCCGCAGCGGGTCCCCGCGCACGGGCGCGGACGGGGAGCATCGACGTCATCGC
GCGCACCGCAGGCCCGGGGAGGAGGGTCCGGAGGACAAGGCGGAGCGGAGGGCGCGGCAC
CGCGAGGGCAGCCGGCCGGCCCGGGGCGGCGAGGGCGAGGGCGAGGGCCCCGACGGGGGC
GAGCGCAGGAGAAGGCACCGGCATGGCGCTCCAGCCACGTACGAGGGGGACGCGCGGAGG
GAGGACAAGGAGCGGAGGCATCGGAGGAGGAAAGAGAACCAGGGCTCCGGGGTCCCTGTG
TCGGGCCCCAACCTGTCAACCACCCGGCCAATCCAGCAGGACCTGGGCCGCCAAGACCCA
CCCCTGGCAGAGGATATTGACAACATGAAGAACAACAAGCTGGCCACCGCGGAGTCGGCC
GCTCCCCACGGCAGCCTTGGCCACGCCGGCCTGCCCCAGAGCCCAGCCAAGATGGGAAAC
AGCACCGACCCCGGCCCCATGCTGGCCATCCCTGCCATGGCCACCAACCCCCAGAACGCC
GCCAGCCGCCGGACGCCCAACAACCCGGGGAACCCATCCAATCCCGGCCCCCCCAAGACC
CCCGAGAATAGCCTTATCGTCACCAACCCCAGCGGCACCCAGACCAATTCAGCTAAGACT
GCCAGGAAACCCGACCACACCACAGTGGACATCCCCCCAGCCTGCCCACCCCCCCTCAAC
CACACCGTCGTACAAGTGAACAAAAACGCCAACCCAGACCCACTGCCAAAAAAAGAGGAA
GAGAAGAAGGAGGAGGAGGAAGACGACCGTGGGGAAGACGGCCCTAAGCCAATGCCTCCC
TATAGCTCCATGTTCATCCTGTCCACGACCAACCCCCTTCGCCGCCTGTGCCATTACATC
CTGAACCTGCGCTACTTTGAGATGTGCATCCTCATGGTCATTGCCATGAGCAGCATCGCC
CTGGCCGCCGAGGACCCTGTGCAGCCCAACGCACCTCGGAACAACGTGCTGCGATACTTT
GACTACGTTTTTACAGGCGTCTTTACCTTTGAGATGGTGATCAAGATGATTGACCTGGGG
CTCGTCCTGCATCAGGGTGCCTACTTCCGTGACCTCTGGAATATTCTCGACTTCATAGTG
GTCAGTGGGGCCCTGGTAGCCTTTGCCTTCACTGGCAATAGCAAAGGAAAAGACATCAAC
ACGATTAAATCCCTCCGAGTCCTCCGGGTGCTACGACCTCTTAAAACCATCAAGCGGCTG
CCAAAGCTCAAGGCTGTGTTTGACTGTGTGGTGAACTCACTTAAAAACGTCTTCAACATC
CTCATCGTCTACATGCTATTCATGTTCATCTTCGCCGTGGTGGCTGTGCAGCTCTTCAAG
GGGAAATTCTTCCACTGCACTGACGAGTCCAAAGAGTTTGAGAAAGATTGTCGAGGCAAA
TACCTCCTCTACGAGAAGAATGAGGTGAAGGCGCGAGACCGGGAGTGGAAGAAGTATGAA
TTCCATTACGACAATGTGCTGTGGGCTCTGCTGACCCTCTTCACCGTGTCCACGGGAGAA
GGCTGGCCACAGGTCCTCAAGCATTCGGTGGACGCCACCTTTGAGAACCAGGGCCCCAGC
CCCGGGTACCGCATGGAGATGTCCATTTTCTACGTCGTCTACTTTGTGGTGTTCCCCTTC
TTCTTTGTCAATATCTTTGTGGCCTTGATCATCATCACCTTCCAGGAGCAAGGGGACAAG
ATGATGGAGGAATACAGCCTGGAGAAAAATGAGAGGGCCTGCATTGATTTCGCCATCAGC
GCCAAGCCGCTGACCCGACACATGCCGCAGAACAAGCAGAGCTTCCAGTACCGCATGTGG
CAGTTCGTGGTGTCTCCGCCTTTCGAGTACACGATCATGGCCATGATCGCCCTCAACACC
ATCGTGCTTATGATGAAGTTCTATGGGGCTTCTGTTGCTTATGAAAATGCCCTGCGGGTG
TTCAACATCGTCTTCACCTCCCTCTTCTCTCTGGAATGTGTGCTGAAAGTCATGGCTTTT
GGGATTCTGAATTATTTCCGCGATGCCTGGAACATCTTCGACTTTGTGACTGTTCTGGGC
AGCATCACCGATATCCTCGTGACTGAGTTTGGGAATAACTTCATCAACCTGAGCTTTCTC
CGCCTCTTCCGAGCTGCCCGGCTCATCAAACTTCTCCGTCAGGGTTACACCATCCGCATT
CTTCTCTGGACCTTTGTGCAGTCCTTCAAGGCCCTGCCTTATGTCTGTCTGCTGATCGCC
ATGCTCTTCTTCATCTATGCCATCATTGGGATGCAGGTGTTTGGTAACATTGGCATCGAC
GTGGAGGACGAGGACAGTGATGAAGATGAGTTCCAAATCACTGAGCACAATAACTTCCGG
ACCTTCTTCCAGGCCCTCATGCTTCTCTTCCGGAGTGCCACCGGGGAAGCTTGGCACAAC
ATCATGCTTTCCTGCCTCAGCGGGAAACCGTGTGATAAGAACTCTGGCATCCTGACTCGA
GAGTGTGGCAATGAATTTGCTTATTTTTACTTTGTTTCCTTCATCTTCCTCTGCTCGTTT
CTGATGCTGAATCTCTTTGTCGCCGTCATCATGGACAACTTTGAGTACCTCACCCGAGAC
TCCTCCATCCTGGGCCCCCACCACCTGGATGAGTACGTGCGTGTCTGGGCCGAGTATGAC
CCCGCAGCTTGCGGTCGGATTCATTATAAGGATATGTACAGTTTATTACGAGTAATATCT
CCCCCTCTCGGCTTAGGCAAGAAATGTCCTCATAGGGTTGCTTGCAAGCGGCTTCTGCGG
ATGGACCTGCCCGTCGCAGATGACAACACCGTCCACTTCAATTCCACCCTCATGGCTCTG
ATCCGCACAGCCCTGGACATCAAGATTGCCAAGGGAGGAGCCGACAAACAGCAGATGGAC
GCTGAGCTGCGGAAGGAGATGATGGCGATTTGGCCCAATCTGTCCCAGAAGACGCTAGAC
CTGCTGGTCACACCTCACAAGTCCACGGACCTCACCGTGGGGAAGATCTACGCAGCCATG
ATGATCATGGAGTACTACCGGCAGAGCAAGGCCAAGAAGCTGCAGGCCATGCGCGAGGAG
CAGGACCGGACACCCCTCATGTTCCAGCGCATGGAGCCCCCGTCCCCAACGCAGGAAGGG
GGACCTGGCCAGAACGCCCTCCCCTCCACCCAGCTGGACCCAGGAGGAGCCCTGATGGCT
CACGAAAGCGGCCTCAAGGAGAGCCCGTCCTGGGTGACCCAGCGTGCCCAGGAGATGTTC
CAGAAGACGGGCACATGGAGTCCGGAACAAGGCCCCCCTACCGACATGCCCAACAGCCAG
CCTAACTCTCAGTCCGTGGAGATGCGAGAGATGGGCAGAGATGGCTACTCCGACAGCGAG
CACTACCTCCCCATGGAAGGCCAGGGCCGGGCTGCCTCCATGCCCCGCCTCCCTGCAGAG
AACCAGAGGAGAAGGGGCCGGCCACGTGGGAATAACCTCAGTACCATCTCAGACACCAGC
CCCATGAAGCGTTCAGCCTCCGTGCTGGGCCCCAAGGCCCGACGCCTGGACGATTACTCG
CTGGAGCGGGTCCCGCCCGAGGAGAACCAGCGGCACCACCAGCGGCGCCGCGACCGCAGC
CACCGCGCCTCTGAGCGCTCCCTGGGCCGCTACACCGATGTGGACACAGGCTTGGGGACA
GACCTGAGCATGACCACCCAATCCGGGGACCTGCCGTCGAAGGAGCGGGACCAGGAGCGG
GGCCGGCCCAAGGATCGGAAGCATCGACAGCACCACCACCACCACCACCACCACCACCAT
CCCCCGCCCCCCGACAAGGACCGCTATGCCCAGGAACGGCCGGACCACGGCCGGGCACGG
GCTCGGGACCAGCGCTGGTCCCGCTCGCCCAGCGAGGGCCGAGAGCACATGGCGCACCGG
CAGGGCAGTAGTTCCGTAAGTGGAAGCCCAGCCCCCTCAACATCTGGTACCAGCACTCCG
CGGCGGGGCCGCCGCCAGCTCCCCCAGACCCCCTCCACCCCCCGGCCACACGTGTCCTAT
TCCCCTGTGATCCGTAAGGCCGGCGGCTCGGGGCCCCCGCAGCAGCAGCAGCAGCAGCAG
CAGCAGCAGCAGGCGGTGGCCAGGCCGGGCCGGGCGGCCACCAGCGGCCCTCGGAGGTAC
CCAGGCCCCACGGCCGAGCCTCTGGCCGGAGATCGGCCGCCCACGGGGGGCCACAGCAGC
GGCCGCTCGCCCAGGATGGAGAGGCGGGTCCCAGGCCCGGCCCGGAGCGAGTCCCCCAGG
GCCTGTCGACACGGCGGGGCCCGGTGGCCGGCATCTGGCCCGCACGTGTCCGAGGGGCCC
CCGGGTCCCCGGCACCATGGCTACTACCGGGGCTCCGACTACGACGAGGCCGATGGCCCG
GGCAGCGGGGGCGGCGAGGAGGCCATGGCCGGGGCCTACGACGCGCCACCCCCCGTACGA
CACGCGTCCTCGGGCGCCACCGGGCGCTCGCCCAGGACTCCCCGGGCCTCGGGCCCGGCC
TGCGCCTCGCCTTCTCGGCACGGCCGGCGACTCCCCAACGGCTACTACCCGGCGCACGGA
CTGGCCAGGCCCCGCGGGCCGGGCTCCAGGAAGGGCCTGCACGAACCCTACAGCGAGAGT
GACGATGATTGGTGCTAA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>2505</residue_number>
    <molecular_weight>282362.4</molecular_weight>
    <theoretical_pi>9.1</theoretical_pi>
    <pfams>
      <pfam>
        <name>Ca_chan_IQ</name>
        <pfam_id>PF08763</pfam_id>
      </pfam>
      <pfam>
        <name>Ion_trans</name>
        <pfam_id>PF00520</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
      <region>99-117</region>
      <region>136-155</region>
      <region>168-185</region>
      <region>191-209</region>
      <region>229-248</region>
      <region>336-360</region>
      <region>488-506</region>
      <region>522-541</region>
      <region>550-568</region>
      <region>579-597</region>
      <region>617-636</region>
      <region>690-714</region>
      <region>1243-1261</region>
      <region>1278-1297</region>
      <region>1310-1328</region>
      <region>1340-1358</region>
      <region>1378-1397</region>
      <region>1485-1509</region>
      <region>1565-1593</region>
      <region>1599-1618</region>
      <region>1627-1645</region>
      <region>1653-1671</region>
      <region>1691-1710</region>
      <region>1783-1807</region>
    </transmembrane_regions>
    <signal_regions>
      <region>None</region>
    </signal_regions>
    <protein_sequence>&gt;Voltage-dependent P/Q-type calcium channel subunit alpha-1A
MARFGDEMPARYGGGGSGAAAGVVVGSGGGRGAGGSRQGGQPGAQRMYKQSMAQRARTMA
LYNPIPVRQNCLTVNRSLFLFSEDNVVRKYAKKITEWPPFEYMILATIIANCIVLALEQH
LPDDDKTPMSERLDDTEPYFIGIFCFEAGIKIIALGFAFHKGSYLRNGWNVMDFVVVLTG
ILATVGTEFDLRTLRAVRVLRPLKLVSGIPSLQVVLKSIMKAMIPLLQIGLLLFFAILIF
AIIGLEFYMGKFHTTCFEEGTDDIQGESPAPCGTEEPARTCPNGTKCQPYWEGPNNGITQ
FDNILFAVLTVFQCITMEGWTDLLYNSNDASGNTWNWLYFIPLIIIGSFFMLNLVLGVLS
GEFAKERERVENRRAFLKLRRQQQIERELNGYMEWISKAEEVILAEDETDGEQRHPFDGA
LRRTTIKKSKTDLLNPEEAEDQLADIASVGSPFARASIKSAKLENSTFFHKKERRMRFYI
RRMVKTQAFYWTVLSLVALNTLCVAIVHYNQPEWLSDFLYYAEFIFLGLFMSEMFIKMYG
LGTRPYFHSSFNCFDCGVIIGSIFEVIWAVIKPGTSFGISVLRALRLLRIFKVTKYWASL
RNLVVSLLNSMKSIISLLFLLFLFIVVFALLGMQLFGGQFNFDEGTPPTNFDTFPAAIMT
VFQILTGEDWNEVMYDGIKSQGGVQGGMVFSIYFIVLTLFGNYTLLNVFLAIAVDNLANA
QELTKDEQEEEEAANQKLALQKAKEVAEVSPLSAANMSIAVKEQQKNQKPAKSVWEQRTS
EMRKQNLLASREALYNEMDPDERWKAAYTRHLRPDMKTHLDRPLVVDPQENRNNNTNKSR
AAEPTVDQRLGQQRAEDFLRKQARYHDRARDPSGSAGLDARRPWAGSQEAELSREGPYGR
ESDHHAREGSLEQPGFWEGEAERGKAGDPHRRHVHRQGGSRESRSGSPRTGADGEHRRHR
AHRRPGEEGPEDKAERRARHREGSRPARGGEGEGEGPDGGERRRRHRHGAPATYEGDARR
EDKERRHRRRKENQGSGVPVSGPNLSTTRPIQQDLGRQDPPLAEDIDNMKNNKLATAESA
APHGSLGHAGLPQSPAKMGNSTDPGPMLAIPAMATNPQNAASRRTPNNPGNPSNPGPPKT
PENSLIVTNPSGTQTNSAKTARKPDHTTVDIPPACPPPLNHTVVQVNKNANPDPLPKKEE
EKKEEEEDDRGEDGPKPMPPYSSMFILSTTNPLRRLCHYILNLRYFEMCILMVIAMSSIA
LAAEDPVQPNAPRNNVLRYFDYVFTGVFTFEMVIKMIDLGLVLHQGAYFRDLWNILDFIV
VSGALVAFAFTGNSKGKDINTIKSLRVLRVLRPLKTIKRLPKLKAVFDCVVNSLKNVFNI
LIVYMLFMFIFAVVAVQLFKGKFFHCTDESKEFEKDCRGKYLLYEKNEVKARDREWKKYE
FHYDNVLWALLTLFTVSTGEGWPQVLKHSVDATFENQGPSPGYRMEMSIFYVVYFVVFPF
FFVNIFVALIIITFQEQGDKMMEEYSLEKNERACIDFAISAKPLTRHMPQNKQSFQYRMW
QFVVSPPFEYTIMAMIALNTIVLMMKFYGASVAYENALRVFNIVFTSLFSLECVLKVMAF
GILNYFRDAWNIFDFVTVLGSITDILVTEFGNNFINLSFLRLFRAARLIKLLRQGYTIRI
LLWTFVQSFKALPYVCLLIAMLFFIYAIIGMQVFGNIGIDVEDEDSDEDEFQITEHNNFR
TFFQALMLLFRSATGEAWHNIMLSCLSGKPCDKNSGILTRECGNEFAYFYFVSFIFLCSF
LMLNLFVAVIMDNFEYLTRDSSILGPHHLDEYVRVWAEYDPAAWGRMPYLDMYQMLRHMS
PPLGLGKKCPARVAYKRLLRMDLPVADDNTVHFNSTLMALIRTALDIKIAKGGADKQQMD
AELRKEMMAIWPNLSQKTLDLLVTPHKSTDLTVGKIYAAMMIMEYYRQSKAKKLQAMREE
QDRTPLMFQRMEPPSPTQEGGPGQNALPSTQLDPGGALMAHESGLKESPSWVTQRAQEMF
QKTGTWSPEQGPPTDMPNSQPNSQSVEMREMGRDGYSDSEHYLPMEGQGRAASMPRLPAE
NQRRRGRPRGNNLSTISDTSPMKRSASVLGPKARRLDDYSLERVPPEENQRHHQRRRDRS
HRASERSLGRYTDVDTGLGTDLSMTTQSGDLPSKERDQERGRPKDRKHRQHHHHHHHHHH
PPPPDKDRYAQERPDHGRARARDQRWSRSPSEGREHMAHRQGSSSVSGSPAPSTSGTSTP
RRGRRQLPQTPSTPRPHVSYSPVIRKAGGSGPPQQQQQQQQQQQAVARPGRAATSGPRRY
PGPTAEPLAGDRPPTGGHSSGRSPRMERRVPGPARSESPRACRHGGARWPASGPHVSEGP
PGPRHHGYYRGSDYDEADGPGSGGGEEAMAGAYDAPPPVRHASSGATGRSPRTPRASGPA
CASPSRHGRRLPNGYYPAHGLARPRGPGSRKGLHEPYSESDDDWC</protein_sequence>
  </protein_properties>
  <genbank_protein_id>2281752</genbank_protein_id>
  <uniprot_id>O00555</uniprot_id>
  <uniprot_name>CAC1A_HUMAN</uniprot_name>
  <pdb_ids>
  </pdb_ids>
  <genbank_gene_id>U79666</genbank_gene_id>
  <genecard_id>CACNA1A</genecard_id>
  <geneatlas_id>CACNA1A</geneatlas_id>
  <hgnc_id>HGNC:1388</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Hans M, Urrutia A, Deal C, Brust PF, Stauderman K, Ellis SB, Harpold MM, Johnson EC, Williams ME: Structural elements in domain IV that influence biophysical and pharmacological properties of human alpha1A-containing high-voltage-activated calcium channels. Biophys J. 1999 Mar;76(3):1384-400.</reference_text>
      <pubmed_id>10049321</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ophoff RA, Terwindt GM, Vergouwe MN, van Eijk R, Oefner PJ, Hoffman SM, Lamerdin JE, Mohrenweiser HW, Bulman DE, Ferrari M, Haan J, Lindhout D, van Ommen GJ, Hofker MH, Ferrari MD, Frants RR: Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell. 1996 Nov 1;87(3):543-52.</reference_text>
      <pubmed_id>8898206</pubmed_id>
    </reference>
    <reference>
      <reference_text>Zhuchenko O, Bailey J, Bonnen P, Ashizawa T, Stockton DW, Amos C, Dobyns WB, Subramony SH, Zoghbi HY, Lee CC: Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel. Nat Genet. 1997 Jan;15(1):62-9.</reference_text>
      <pubmed_id>8988170</pubmed_id>
    </reference>
    <reference>
      <reference_text>Grimwood J, Gordon LA, Olsen A, Terry A, Schmutz J, Lamerdin J, Hellsten U, Goodstein D, Couronne O, Tran-Gyamfi M, Aerts A, Altherr M, Ashworth L, Bajorek E, Black S, Branscomb E, Caenepeel S, Carrano A, Caoile C, Chan YM, Christensen M, Cleland CA, Copeland A, Dalin E, Dehal P, Denys M, Detter JC, Escobar J, Flowers D, Fotopulos D, Garcia C, Georgescu AM, Glavina T, Gomez M, Gonzales E, Groza M, Hammon N, Hawkins T, Haydu L, Ho I, Huang W, Israni S, Jett J, Kadner K, Kimball H, Kobayashi A, Larionov V, Leem SH, Lopez F, Lou Y, Lowry S, Malfatti S, Martinez D, McCready P, Medina C, Morgan J, Nelson K, Nolan M, Ovcharenko I, Pitluck S, Pollard M, Popkie AP, Predki P, Quan G, Ramirez L, Rash S, Retterer J, Rodriguez A, Rogers S, Salamov A, Salazar A, She X, Smith D, Slezak T, Solovyev V, Thayer N, Tice H, Tsai M, Ustaszewska A, Vo N, Wagner M, Wheeler J, Wu K, Xie G, Yang J, Dubchak I, Furey TS, DeJong P, Dickson M, Gordon D, Eichler EE, Pennacchio LA, Richardson P, Stubbs L, Rokhsar DS, Myers RM, Rubin EM, Lucas SM: The DNA sequence and biology of human chromosome 19.  Nature. 2004 Apr 1;428(6982):529-35.</reference_text>
      <pubmed_id>15057824</pubmed_id>
    </reference>
    <reference>
      <reference_text>Barry EL, Viglione MP, Kim YI, Froehner SC: Expression and antibody inhibition of P-type calcium channels in human small-cell lung carcinoma cells. J Neurosci. 1995 Jan;15(1 Pt 1):274-83.</reference_text>
      <pubmed_id>7823133</pubmed_id>
    </reference>
    <reference>
      <reference_text>Oguro-Okano M, Griesmann GE, Wieben ED, Slaymaker SJ, Snutch TP, Lennon VA: Molecular diversity of neuronal-type calcium channels identified in small cell lung carcinoma. Mayo Clin Proc. 1992 Dec;67(12):1150-9.</reference_text>
      <pubmed_id>1335101</pubmed_id>
    </reference>
    <reference>
      <reference_text>Margolis RL, Breschel TS, Li SH, Kidwai AS, Antonarakis SE, McInnis MG, Ross CA: Characterization of cDNA clones containing CCA trinucleotide repeats derived from human brain. Somat Cell Mol Genet. 1995 Jul;21(4):279-84.</reference_text>
      <pubmed_id>8525433</pubmed_id>
    </reference>
    <reference>
      <reference_text>Lee A, Westenbroek RE, Haeseleer F, Palczewski K, Scheuer T, Catterall WA: Differential modulation of Ca(v)2.1 channels by calmodulin and Ca2+-binding protein 1. Nat Neurosci. 2002 Mar;5(3):210-7.</reference_text>
      <pubmed_id>11865310</pubmed_id>
    </reference>
    <reference>
      <reference_text>Mori MX, Vander Kooi CW, Leahy DJ, Yue DT: Crystal structure of the CaV2 IQ domain in complex with Ca2+/calmodulin: high-resolution mechanistic implications for channel regulation by Ca2+. Structure. 2008 Apr;16(4):607-20.</reference_text>
      <pubmed_id>18400181</pubmed_id>
    </reference>
    <reference>
      <reference_text>Yue Q, Jen JC, Nelson SF, Baloh RW: Progressive ataxia due to a missense mutation in a calcium-channel gene.  Am J Hum Genet. 1997 Nov;61(5):1078-87.</reference_text>
      <pubmed_id>9345107</pubmed_id>
    </reference>
    <reference>
      <reference_text>Jodice C, Mantuano E, Veneziano L, Trettel F, Sabbadini G, Calandriello L, Francia A, Spadaro M, Pierelli F, Salvi F, Ophoff RA, Frants RR, Frontali M: Episodic ataxia type 2 (EA2) and spinocerebellar ataxia type 6 (SCA6) due to CAG repeat expansion in the CACNA1A gene on chromosome 19p. Hum Mol Genet. 1997 Oct;6(11):1973-8.</reference_text>
      <pubmed_id>9302278</pubmed_id>
    </reference>
    <reference>
      <reference_text>Friend KL, Crimmins D, Phan TG, Sue CM, Colley A, Fung VS, Morris JG, Sutherland GR, Richards RI: Detection of a novel missense mutation and second recurrent mutation in the CACNA1A gene in individuals with EA-2 and FHM. Hum Genet. 1999 Sep;105(3):261-5.</reference_text>
      <pubmed_id>10987655</pubmed_id>
    </reference>
    <reference>
      <reference_text>Carrera P, Piatti M, Stenirri S, Grimaldi LM, Marchioni E, Curcio M, Righetti PG, Ferrari M, Gelfi C: Genetic heterogeneity in Italian families with familial hemiplegic migraine. Neurology. 1999 Jul 13;53(1):26-33.</reference_text>
      <pubmed_id>10408532</pubmed_id>
    </reference>
    <reference>
      <reference_text>Kors EE, Terwindt GM, Vermeulen FL, Fitzsimons RB, Jardine PE, Heywood P, Love S, van den Maagdenberg AM, Haan J, Frants RR, Ferrari MD: Delayed cerebral edema and fatal coma after minor head trauma: role of the CACNA1A calcium channel subunit gene and relationship with familial hemiplegic migraine. Ann Neurol. 2001 Jun;49(6):753-60.</reference_text>
      <pubmed_id>11409427</pubmed_id>
    </reference>
    <reference>
      <reference_text>Denier C, Ducros A, Durr A, Eymard B, Chassande B, Tournier-Lasserve E: Missense CACNA1A mutation causing episodic ataxia type 2.  Arch Neurol. 2001 Feb;58(2):292-5.</reference_text>
      <pubmed_id>11176968</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ducros A, Denier C, Joutel A, Cecillon M, Lescoat C, Vahedi K, Darcel F, Vicaut E, Bousser MG, Tournier-Lasserve E: The clinical spectrum of familial hemiplegic migraine associated with mutations in a neuronal calcium channel. N Engl J Med. 2001 Jul 5;345(1):17-24.</reference_text>
      <pubmed_id>11439943</pubmed_id>
    </reference>
    <reference>
      <reference_text>Jen J, Wan J, Graves M, Yu H, Mock AF, Coulin CJ, Kim G, Yue Q, Papazian DM, Baloh RW: Loss-of-function EA2 mutations are associated with impaired neuromuscular transmission. Neurology. 2001 Nov 27;57(10):1843-8.</reference_text>
      <pubmed_id>11723274</pubmed_id>
    </reference>
    <reference>
      <reference_text>van den Maagdenberg AM, Kors EE, Brunt ER, van Paesschen W, Pascual J, Ravine D, Keeling S, Vanmolkot KR, Vermeulen FL, Terwindt GM, Haan J, Frants RR, Ferrari MD: Episodic ataxia type 2. Three novel truncating mutations and one novel missense mutation in the CACNA1A gene. J Neurol. 2002 Nov;249(11):1515-9.</reference_text>
      <pubmed_id>12420090</pubmed_id>
    </reference>
    <reference>
      <reference_text>Spacey SD, Hildebrand ME, Materek LA, Bird TD, Snutch TP: Functional implications of a novel EA2 mutation in the P/Q-type calcium channel. Ann Neurol. 2004 Aug;56(2):213-20.</reference_text>
      <pubmed_id>15293273</pubmed_id>
    </reference>
    <reference>
      <reference_text>Alonso I, Barros J, Tuna A, Seixas A, Coutinho P, Sequeiros J, Silveira I: A novel R1347Q mutation in the predicted voltage sensor segment of the P/Q-type calcium-channel alpha-subunit in a family with progressive cerebellar ataxia and hemiplegic migraine. Clin Genet. 2004 Jan;65(1):70-2.</reference_text>
      <pubmed_id>15032980</pubmed_id>
    </reference>
    <reference>
      <reference_text>Mantuano E, Veneziano L, Spadaro M, Giunti P, Guida S, Leggio MG, Verriello L, Wood N, Jodice C, Frontali M: Clusters of non-truncating mutations of P/Q type Ca2+ channel subunit Ca(v)2.1 causing episodic ataxia 2. J Med Genet. 2004 Jun;41(6):e82.</reference_text>
      <pubmed_id>15173248</pubmed_id>
    </reference>
    <reference>
      <reference_text>Jen J, Kim GW, Baloh RW: Clinical spectrum of episodic ataxia type 2.  Neurology. 2004 Jan 13;62(1):17-22.</reference_text>
      <pubmed_id>14718690</pubmed_id>
    </reference>
    <reference>
      <reference_text>von Brevern M, Ta N, Shankar A, Wiste A, Siegel A, Radtke A, Sander T, Escayg A: Migrainous vertigo: mutation analysis of the candidate genes CACNA1A, ATP1A2, SCN1A, and CACNB4. Headache. 2006 Jul-Aug;46(7):1136-41.</reference_text>
      <pubmed_id>16866717</pubmed_id>
    </reference>
    <reference>
      <reference_text>Tonelli A, D'Angelo MG, Salati R, Villa L, Germinasi C, Frattini T, Meola G, Turconi AC, Bresolin N, Bassi MT: Early onset, non fluctuating spinocerebellar ataxia and a novel missense mutation in CACNA1A gene. J Neurol Sci. 2006 Feb 15;241(1-2):13-7. Epub 2005 Dec 2.</reference_text>
      <pubmed_id>16325861</pubmed_id>
    </reference>
    <reference>
      <reference_text>Stam AH, Vanmolkot KR, Kremer HP, Gartner J, Brown J, Leshinsky-Silver E, Gilad R, Kors EE, Frankhuizen WS, Ginjaar HB, Haan J, Frants RR, Ferrari MD, van den Maagdenberg AM, Terwindt GM: CACNA1A R1347Q: a frequent recurrent mutation in hemiplegic migraine.  Clin Genet. 2008 Nov;74(5):481-5. Epub 2008 Apr 8.</reference_text>
      <pubmed_id>18400034</pubmed_id>
    </reference>
    <reference>
      <reference_text>Zafeiriou DI, Lehmann-Horn F, Vargiami E, Teflioudi E, Ververi A, Jurkat-Rott K: Episodic ataxia type 2 showing ictal hyperhidrosis with hypothermia and interictal chronic diarrhea due to a novel CACNA1A mutation. Eur J Paediatr Neurol. 2009 Mar;13(2):191-3. Epub 2008 Jul 3.</reference_text>
      <pubmed_id>18602318</pubmed_id>
    </reference>
    <reference>
      <reference_text>Cuenca-Leon E, Banchs I, Serra SA, Latorre P, Fernandez-Castillo N, Corominas R, Valverde MA, Volpini V, Fernandez-Fernandez JM, Macaya A, Cormand B: Late-onset episodic ataxia type 2 associated with a novel loss-of-function mutation in the CACNA1A gene. J Neurol Sci. 2009 May 15;280(1-2):10-4. Epub 2009 Feb 20.</reference_text>
      <pubmed_id>19232643</pubmed_id>
    </reference>
    <reference>
      <reference_text>D'Onofrio M, Ambrosini A, Di Mambro A, Arisi I, Santorelli FM, Grieco GS, Nicoletti F, Nappi G, Pierelli F, Schoenen J, Buzzi MG: The interplay of two single nucleotide polymorphisms in the CACNA1A gene may contribute to migraine susceptibility. Neurosci Lett. 2009 Mar 27;453(1):12-5. Epub 2009 Feb 4.</reference_text>
      <pubmed_id>19429006</pubmed_id>
    </reference>
    <reference>
      <reference_text>Romaniello R, Zucca C, Tonelli A, Bonato S, Baschirotto C, Zanotta N, Epifanio R, Righini A, Bresolin N, Bassi MT, Borgatti R: A wide spectrum of clinical, neurophysiological and neuroradiological abnormalities in a family with a novel CACNA1A mutation. J Neurol Neurosurg Psychiatry. 2010 Aug;81(8):840-3.</reference_text>
      <pubmed_id>20682717</pubmed_id>
    </reference>
    <reference>
      <reference_text>Mantuano E, Romano S, Veneziano L, Gellera C, Castellotti B, Caimi S, Testa D, Estienne M, Zorzi G, Bugiani M, Rajabally YA, Barcina MJ, Servidei S, Panico A, Frontali M, Mariotti C: Identification of novel and recurrent CACNA1A gene mutations in fifteen patients with episodic ataxia type 2. J Neurol Sci. 2010 Apr 15;291(1-2):30-6. Epub 2010 Feb 2.</reference_text>
      <pubmed_id>20129625</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Pregabalin</name>
        <accession>HMDB14375</accession>
      </metabolite>
      <reference>
        <reference_text>Gazulla J, Tintore M: The P/Q-type voltage-dependent calcium channel: a therapeutic target in spinocerebellar ataxia type 6. Acta Neurol Scand. 2007 May;115(5):356-63.</reference_text>
        <pubmed_id>17489948</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pregabalin</name>
        <accession>HMDB14375</accession>
      </metabolite>
      <reference>
        <reference_text>Gazulla J, Tintore MA: The P/Q-type voltage-dependent calcium channel as pharmacological target in spinocerebellar ataxia type 6: gabapentin and pregabalin may be of therapeutic benefit. Med Hypotheses. 2007;68(1):131-6. Epub 2006 Aug 8.</reference_text>
        <pubmed_id>16899342</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pregabalin</name>
        <accession>HMDB14375</accession>
      </metabolite>
      <reference>
        <reference_text>Jacquy J, Lossignol D, Sternon J: [Pregabalin (Lyrica) and neuropathic pain syndromes].  Rev Med Brux. 2006 Sep-Oct;27(5):445-50.</reference_text>
        <pubmed_id>17144644</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pregabalin</name>
        <accession>HMDB14375</accession>
      </metabolite>
      <reference>
        <reference_text>Taylor CP, Angelotti T, Fauman E: Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res. 2007 Feb;73(2):137-50. Epub 2006 Nov 28.</reference_text>
        <pubmed_id>17126531</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pregabalin</name>
        <accession>HMDB14375</accession>
      </metabolite>
      <reference>
        <reference_text>Field MJ, Cox PJ, Stott E, Melrose H, Offord J, Su TZ, Bramwell S, Corradini L, England S, Winks J, Kinloch RA, Hendrich J, Dolphin AC, Webb T, Williams D: Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17537-42. Epub 2006 Nov 6.</reference_text>
        <pubmed_id>17088553</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25.</reference_text>
        <pubmed_id>19125880</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bepridil</name>
        <accession>HMDB15374</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bepridil</name>
        <accession>HMDB15374</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bepridil</name>
        <accession>HMDB15374</accession>
      </metabolite>
      <reference>
        <reference_text>Bezprozvanny I, Tsien RW: Voltage-dependent blockade of diverse types of voltage-gated Ca2+ channels expressed in Xenopus oocytes by the Ca2+ channel antagonist mibefradil (Ro 40-5967). Mol Pharmacol. 1995 Sep;48(3):540-9.</reference_text>
        <pubmed_id>7565636</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
